vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February

vTv Therapeutics Inc. (NASDAQ:VTVT) saw a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 50,829 shares, a growth of 61.2% from the January 29th total of 31,525 shares. Based on an average trading volume of 28,349 shares, the short-interest ratio is presently 1.8 days. Approximately 1.3% of the shares of the stock are short sold. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 28,349 shares, the short-interest ratio is presently 1.8 days.

Institutional Investors Weigh In On vTv Therapeutics

Several hedge funds have recently bought and sold shares of the business. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $731,000. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics in the 4th quarter worth $221,000. Finally, Baker BROS. Advisors LP raised its stake in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Trading Down 3.0%

Shares of NASDAQ VTVT opened at $38.16 on Friday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The firm has a market capitalization of $150.35 million, a PE ratio of -11.49 and a beta of 0.50. The firm has a fifty day simple moving average of $36.56 and a two-hundred day simple moving average of $28.02.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on VTVT shares. Wall Street Zen raised vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Roth Mkm started coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. Finally, BTIG Research reaffirmed a “buy” rating and set a $49.00 price objective (up from $40.00) on shares of vTv Therapeutics in a research note on Tuesday, January 27th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $55.25.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.